The underlying mechanism of chimeric antigen receptor (CAR)-T cell therapy triggering secondary T-cell cancers: Mystery of the Sphinx?

Zhou, Zhaokai; Zhang, Ge; Xu, Yudi; Yang, Shuai; Wang, Jiaojiao; Li, Zhengrui; Peng, Fu; Lu, Qiong

doi:10.1016/j.canlet.2024.217083

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

2025

Publication Types

Select...

Article2

Preprint1

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Engraftment of a surrogate antigen onto tumor cell surface via pHLIP peptide to universally target CAR-T cell therapy to solid tumors

Zhang,

Fu,

Ting Lim

et al. 2025

Cancer Letters

View full text Add to dashboard Cite

Engraftment of a surrogate antigen onto tumor cell surface via pHLIP peptide to universally target CAR-T cell therapy to solid tumors

Zhang,

Fu,

Ting Lim

et al. 2025

Cancer Letters

View full text Add to dashboard Cite

Revolutionising Cancer Immunotherapy: Advancements and Prospects in Non‐Viral CAR‐NK Cell Engineering

Zhou,

Chen,

et al. 2024

Cell Proliferation

View full text Add to dashboard Cite

The recent advancements in cancer immunotherapy have spotlighted the potential of natural killer (NK) cells, particularly chimeric antigen receptor (CAR)–transduced NK cells. These cells, pivotal in innate immunity, offer a rapid and potent response against cancer cells and pathogens without the need for prior sensitization or recognition of peptide antigens. Although NK cell genetic modification is evolving, the viral transduction method continues to be inefficient and fraught with risks, often resulting in cytotoxic outcomes and the possibility of insertional mutagenesis. Consequently, there has been a surge in the development of non‐viral transfection technologies to overcome these challenges in NK cell engineering. Non‐viral approaches for CAR‐NK cell generation are becoming increasingly essential. Cutting‐edge techniques such as trogocytosis, electroporation, lipid nanoparticle (LNP) delivery, clustered regularly interspaced short palindromic repeats–associated protein 9 (CRISPR‐Cas9) gene editing and transposons not only enhance the efficiency and safety of CAR‐NK cell engineering but also open new avenues for novel therapeutic possibilities. Additionally, the infusion of technologies already successful in CAR T‐cell therapy into the CAR‐NK paradigm holds immense potential for further advancements. In this review, we present an overview of the potential of NK cells in cancer immunotherapies, as well as non‐viral transfection technologies for engineering NK cells.

show abstract

Engraftment of a Surrogate Antigen Onto Tumor Cell Surface Via Phlip Peptide to Universally Target Car-T Cell Therapy to Solid Tumors

Zhang,

Lim

et al. 2024

Preprint

View full text Add to dashboard Cite

The underlying mechanism of chimeric antigen receptor (CAR)-T cell therapy triggering secondary T-cell cancers: Mystery of the Sphinx?

Cited by 3 publications

References 47 publications

Engraftment of a surrogate antigen onto tumor cell surface via pHLIP peptide to universally target CAR-T cell therapy to solid tumors

Engraftment of a surrogate antigen onto tumor cell surface via pHLIP peptide to universally target CAR-T cell therapy to solid tumors

Revolutionising Cancer Immunotherapy: Advancements and Prospects in Non‐Viral CAR‐NK Cell Engineering

Engraftment of a Surrogate Antigen Onto Tumor Cell Surface Via Phlip Peptide to Universally Target Car-T Cell Therapy to Solid Tumors

Contact Info

Product

Resources

About